Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anakinra.

Risto S Cvetkovic1, Gillian Keating

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|August 28, 2002
PubMed
Summary
This summary is machine-generated.

Anakinra, a biologic agent blocking interleukin-1 (IL-1), improved rheumatoid arthritis response rates and slowed disease progression in a 6-month trial. Higher doses (150 mg/day) showed significant benefits over placebo, while lower doses did not.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spotlight on peginterferon-alpha-2a (40 kD) plus ribavirin in the management of chronic hepatitis C mono-infection.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2009
Same author

Peginterferon-alpha-2a (40 kD) plus ribavirin: a review of its use in the management of chronic hepatitis C mono-infection.

Drugs·2008
Same author

Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis.

Drugs·2007
Same author

Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea).

Drugs·2007
Same author

Adalimumab: a review of its use in adult patients with rheumatoid arthritis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2006
Same author

Spotlight on rituximab in non-Hodgkin lymphoma and chronic lymphocytic leukemia.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2006
Same journal

Ustekinumab Biosimilars versus Reference Ustekinumab for Moderate-to-Severe Plaque Psoriasis: A Pre-switch Systematic Review and Meta-analysis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Correction: Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Gene Therapy Strategies for Uveal Melanoma: Adeno-associated Virus Delivery Challenges and Translational Opportunities.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Review of Quality Attributes and Analytical Methods Used for Comparative Analytical Assessment of Monoclonal Antibodies as Part of Successful Biosimilar Approvals in the United States and European Union.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose Adalimumab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same journal

An Overview and Trend Analysis of Biosimilar Approvals in China.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
See all related articles

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Rheumatoid arthritis (RA) is a chronic inflammatory disease.
  • Interleukin-1 (IL-1) plays a key role in RA pathogenesis.
  • Anakinra is a recombinant human IL-1 receptor antagonist.

Purpose of the Study:

  • To evaluate the efficacy and safety of anakinra in patients with active, severe or very severe rheumatoid arthritis.
  • To assess the impact of different anakinra dosages on response rates and disease progression.
  • To compare anakinra monotherapy and combination therapy with methotrexate.

Main Methods:

  • A double-blind, randomized trial involving 472 patients with active RA.
  • Subcutaneous administration of anakinra at 30, 75, or 150 mg/day, or placebo, for 6 months.

Related Experiment Videos

  • Assessment of treatment response using American College of Rheumatology (ACR) criteria and productivity days.
  • Evaluation of disease progression using Genant radiographic scores.
  • Comparison of anakinra plus methotrexate versus methotrexate alone.

    • Main Results:

    • Anakinra 150 mg/day significantly increased response rates and productivity days compared to placebo.
    • All anakinra regimens demonstrated a greater slowing of disease progression than placebo.
    • Combined anakinra and methotrexate therapy yielded higher ACR response rates than methotrexate alone.
    • Anakinra was generally well-tolerated, with injection-site reactions being the most common adverse event.
    • Increased incidence of infections was observed in anakinra recipients, but rarely led to discontinuation.

    Conclusions:

    • Anakinra, particularly at 150 mg/day, is effective in treating severe rheumatoid arthritis.
    • Anakinra demonstrates disease-modifying effects by slowing radiographic progression.
    • Combination therapy with anakinra and methotrexate enhances treatment response.
    • Anakinra has an acceptable safety profile, with infections being the main concern.